What is PURE Bioscience?
Headquartered in Rancho Cucamonga, California, PURE Bioscience operates at the intersection of biotechnology and industrial hygiene. The company specializes in the development and commercialization of patented antimicrobial products, most notably its proprietary silver dihydrogen citrate (SDC) technology. Unlike traditional chemical agents, SDC utilizes stabilized ionic silver to provide a broad-spectrum, non-toxic solution for pathogen mitigation. This platform technology is engineered to offer superior efficacy while simultaneously reducing toxicity and preventing the development of bacterial resistance, making it a vital asset for food safety protocols and environmental hygiene management. By integrating SDC into various industrial applications, PURE Bioscience addresses the growing global demand for safer, more sustainable sanitation solutions in food processing and beyond.
How much funding has PURE Bioscience raised?
PURE Bioscience has raised a total of $10.2M across 1 funding round:
Stock Offering
$10.2M
Stock Issuance/Offering (2008): $10.2M, investors not publicly disclosed
Key Investors in PURE Bioscience
Undisclosed Investor
An undisclosed institutional participant providing capital to support the scaling of antimicrobial technology platforms.
Undisclosed Investor
A private equity entity focused on the commercialization of proprietary chemical and biotechnology solutions.
Undisclosed Investor
A strategic backer specializing in early-to-mid stage industrial hygiene and food safety innovation.
What's next for PURE Bioscience?
With the successful completion of this major strategic investment, PURE Bioscience is poised to transition into a more aggressive phase of market penetration and product scaling. The company's roadmap focuses on expanding the adoption of its SDC-based solutions across the food safety supply chain, where regulatory pressures and consumer demand for non-toxic sanitation are at an all-time high. Future growth will likely be driven by strategic partnerships and the continued validation of its antimicrobial platform in diverse industrial environments. As the firm scales, the focus remains on maintaining its technological edge in ionic silver research while optimizing its operational footprint to meet the rigorous requirements of large-scale enterprise clients seeking to mitigate biological risks.
See full PURE Bioscience company page
